Chemical biology approaches to target validation in cancer

Current Opinion in Pharmacology

Volumn 17, Issue , 2014, Pages 87-100

  Blagg, Julian ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DINACICLIB; HEAT SHOCK PROTEIN 90 INHIBITOR; IDELALISIB; INIPARIB; OLAPARIB; THALIDOMIDE DERIVATIVE; VELIPARIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BIOMEDICINE; BREAST CANCER; CANCER GENETICS; CARCINOGENESIS; CHEMICAL BIOLOGY; CHRONIC LYMPHATIC LEUKEMIA; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; FUNCTIONAL GENOMICS; GENE SILENCING; GENETIC LINKAGE; HUMAN; NON SMALL CELL LUNG CANCER; NONHUMAN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TARGET VALIDATION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC EPIGENESIS; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; TRANSLATIONAL RESEARCH;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN INTERACTION MAPS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84908613024     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.07.007     Document Type: Review

References (111)

1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL et al.: Signatures of mutational processes in human cancer. Nature 2013, 500 :415-421.
2. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al.: The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
3. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD et al.: Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW: Cancer genome landscapes. Science 2013, 339:1546-1558.
5. •• Workman P, Al-Lazikani B: Drugging cancer genomes. Nat Rev Drug Discov 2013, 12:889-890. A large-scale computational analysis and commentary from a drug discovery perspective on the public release of massive amounts of data from multiple cancer types. Highlights the need for objective target assessment and prioritization by the drug discovery community to make the best use of such vast amounts of data.
6. Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S et al.: Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 2014, 74:287-297.
7. •• Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B: Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 2013, 12:35-50. Describes an objective, large-scale systematic, multidisciplinary computational assessment of biological and chemical space that can be applied to large gene sets to allow prioritization of cancer targets for further validation and therapeutic exploration, including consideration of biological and druggability assessment and availability of chemical tools. Use of the new knowledgebase, canSAR, is exemplified by the highlighting of a group of druggable but as yet unexplored targets.
8. Burrell RA, McGranahan N, Bartek J, Swanton C: The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
9. Greaves M, Maley CC: Clonal evolution in cancer. Nature 2012, 481:306-313.
10. Crockford A, Jamal-Hanjani M, Hicks J, Swanton C: Implications of intratumour heterogeneity for treatment stratification. J Pathol 2014, 232:264-273.
11. Al-Lazikani B, Banerji U, Workman P: Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012, 30:679-692.
12. Titov DV, Liu JO: Identification and validation of protein targets of bioactive small molecules. Bioorg Med Chem 2012, 20:1902-1909.
13. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ: Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J Med Chem 2012, 55 :4527-4538.
14. Moellering RE, Cravatt BF: How chemoproteomics can enable drug discovery and development. Chem Biol 2012, 19:11-22.
15. Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM et al. : Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. PLOS ONE 2013, 8:e66755.
16. Li X, Rao V, Jin J, Guan B, Anderes KL, Bieberich CJ: Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation index. J Proteome Res 2012, 11:3637-3649.
17. Bunnage ME: Getting pharmaceutical R&D back on target. Nat Chem Biol 2011, 7:335-339.
18. Plenge RM, Scolnick EM, Altshuler D: Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013, 12:581-594.
19. •• Begley CG, Ellis LM: Drug development: raise standards for preclinical cancer research. Nature 2012, 483:531-533. A landmark commentary summarising the current issue of poor data reproducibility in cancer biology related to drug discovery research with recommendations on how to counter this significant issue.
20. • Prinz F, Schlange T, Asadullah K: Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011, 10:712. Using the Bayer experience, the authors illustrate the issue of poor data reproducibility in the context of biological validation for 67 targets, most of which are for oncology indications. Only 20-25% of published findings could be reproduced.
21. Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M: The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst 2010, 102:1284-1296.
22. Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, Kelly G, Saunders B, Howell M, Downward J et al.: Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res 2012, 22:1227-1245.
23. Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A: Functional viability profiles of breast cancer. Cancer Discov 2011, 1:260-273.
24. •• Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, Quackenbush J: Inconsistency in large pharmacogenomic studies. Nature 2013, 504:389-393. The first comprehensive comparison of three large-scale pharmacogenomic studies demonstrating excellent correlation between expression profiles in cell lines profiled across studies but worryingly poor correlation between drug response phenotypes.
25. Collins FS, Tabak LA: Policy: NIH plans to enhance reproducibility. Nature 2014, 505:612-613.
26. •• Bunnage ME, Chekler EL, Jones LH: Target validation using chemical probes. Nat Chem Biol 2013, 9:195-199. Highlights the optimal use of a suite of chemical probes to demonstrate exposure at the site of action, target engagement, functional pharmacology and relevant phenotype, the so-called 'Four Pillars' of cell-based target validation.
27. • Cortés-Cros M, Schmelzle T, Stucke VM, Hofmann F: The path to oncology drug target validation: an industry perspective. Methods Mol Biol 2013, 986:3-13. Excellent overview of target identification and validation approaches in oncology drug discovery.
28. Bunnage ME (Ed): New Frontiers in Chemical Biology, Enabling Drug Discovery. RSC Books; 2011.
29. Workman P: Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003, 2:131-138.
30. Mahmoudi T, Li VS, Ng SS, Taouatas N, Vries RG, Mohammed S, Heck AJ, Clevers H: The kinase TNIK is an essential activator of Wnt target genes. EMBO J 2009, 28 :3329-3340.
31. Ho KK, Parnell KM, Yuan Y, Xu Y, Kultgen SG, Hamblin S, Hendrickson TF, Luo B, Foulks JM, McCullar MV et al.: Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors. Bioorg Med Chem Lett 2013, 23:569-573.
32. Babij C, Zhang Y, Kurzeja RJ, Munzli A, Shehabeldin A, Fernando M, Quon K, Kassner PD, Ruefli-Brasse AA, Watson VJ et al.: STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res 2011, 71 :5818-5826.
33. Smith JR, Clarke PA, de Billy E, Workman P: Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2009, 28:157-169.
34. • Smith JR, de Billy E, Hobbs S, Powers M, Prodromou C, Pearl L, Clarke PA, Workman P: Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. Oncogene 2013 http://dx.doi.org/10.1038/onc.2013.519. The first demonstration that genetic disruption of the CDC37-HSP90 protein interaction does not prevent HSP90-client association, thereby devalidating therapeutic approaches to inhibit the CDC37-HSP90 interaction.
35. •• Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH: Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 2012, 18:1655-1662. Demonstrates that iniparib is unlikely to elicit its cell-based phenotype through inhibition of PARP, thereby countering claims that PARP inhibitors were doomed as a therapeutic class.
36. • Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US et al.: Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012, 18:510-523. Complementary manuscript to that above which proposes an alternative, non-specific, mode of action for iniparib that is consistent with its chemical structure.
37. Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J et al. : A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLOS ONE 2013, 8:e61520.
38. Dantzer F, AméJ-C, Schreiber V, Nakamura J, Ménissier-de Murcia J et al.: Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol 2006, 409:493-510.
39. • Murai J, Huang S-YN, Das BB, Renaud A, Zhang Y et al.: Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012, 72:5588-5599. Trapping of PARP enzymes caused by small molecule inhibitors provides an unusual case of a different pharmacologic effect when comparing genetic silencing and chemical inhibition.
40. Frye SV: The art of the chemical probe. Nat Chem Biol 2010, 6:159-161.
41. Workman P, Collins I: Probing the probes: fitness factors for small molecule tools. Chem Biol 2010, 17:561-577.
42. Zhang L, Holmes IP, Hochgräfe F, Walker SR, Ali NA, Humphrey ES, Wu J, de Silva M, Kersten WJ, Connor T et al.: Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling. J Proteome Res 2013, 12:3104-3116.
43. Bantscheff M, Drewes G: Chemoproteomic approaches to drug target identification and drug profiling. Bioorg Med Chem 2012, 20:1973-1978.
44. Ong SE, Schenone M, Margolin AA, Li X, Do K, Doud MK, Mani DR, Kuai L, Wang X, Wood JL et al.: Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A 2009, 106 :4617-4622.
45. •• Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M: Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012, 11:384-400. A comprehensive review of epigenetic mechanisms and their potential as therapeutic targets.
46. Hewings DS, Rooney TP, Jennings LE, Hay DA, Schofield CJ, Brennan PE, Knapp S, Conway SJ: Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. J Med Chem 2012, 55 :9393-9413.
47. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I et al. : Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
48. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H et al.: Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem 2012, 55:9831-9837.
49. •• James LI, Barsyte-Lovejoy D, Zhong N, Krichevsky L, Korboukh VK, Herold JM, MacNevin CJ, Norris JL, Sagum CA, Tempel W et al.: Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol 2013, 9:184-191. Describes the in vitro and cell-based pharmacology of the first-in-class chemical probe UNC1215 that inhibits the protein-protein interaction of histone methyllysine residues with their corresponding MBT reader domains.
50. Yu W, Smil D, Li F, Tempel W, Fedorov O, Nguyen KT, Bolshan Y, Al-Awar R, Knapp S, Arrowsmith CH et al.: Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg Med Chem 2013, 21:1787-1794.
51. Verma SK, Tian X, LaFrance LV, Duquenne C, Suarex DP, Newlander KA, Romeril SP, Burgess JL, Grant SW, Brackley JA et al.: Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett 2012, 3:1091-1096.
52. • Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, Rougie M et al.: An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 2013, 8:1324-1334. Describes a suite of chemical tools, including the first orally bioavailable chemical probe, and a structurally similar but inactive control, for investigating the role of the lysine methyl transferases EZH1 and EZH2.
53. Sweis RF, Pliushchev M, Brown PJ, Guo J, Li F, Maag D, Petros AM, Soni NB, Tse C, Vedadi M et al. : Discovery and development of potent and selective inhibitors of histone methyltransferase G9a. ACS Med Chem Lett 2014, 5:205-209.
54. Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali- Hassani A, Labrie V, Wigle TJ, Dimaggio PA, Wasney GA, Siarheyeva A et al.: A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2011, 7:566-574.
55. Liu F, Barsyte-Lovejoy D, Li F, Xiong Y, Korboukh V, Huang XP, Allali-Hassani A, Janzen WP, Roth BL, Frye SV et al.: Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem 2013, 56:8931-8942.
56. •• Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H et al.: A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488:404-408. The first disclosure of GSK-J1 a potent and selective inhibitor of the KDM6 class of JMJ demethylases. A structurally similar inactive control compound and a cell-penetrant prodrug are also described.
57. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H et al.: Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
58. •• Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, Ruiz J, Bruick R, Peña-Llopis S, Xu J et al.: A small molecule modulates jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun 2013, 4:2035. The discovery, using a phenotypic cell-based screen, of JIB-04, an inhibitor of the KDM4 subfamily of JMJ demethylases and its associated cell-based and in vivo animal pharmacology.
59. Martin MP, Olesen SH, Georg GI, Schönbrunn E: Cyclindependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol 2013, 8:2360-2365.
60. •• Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S et al.: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 2014, 10:305-312. Influential demonstration of the pharmacological cross-talk between kinase inhibitor scaffolds and bromodomain binding sites. First disclosure of the potential for dual inhibition of kinase and bromodomains at clinically relevant exposures.
61. Downward J: RAS's cloak of invincibility slips at last? Cancer Cell 2014, 25 :5-6.
62. •• Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D et al.: Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 2012, 109:5299-5304. Describes the discovery, by NMR-based fragment screening, of a novel allosteric druggable site on Ras that abrogates oncogenic activity.
63. • Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW: Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 2012, 51:6140-6143. The identification, by NMR-based fragment screening, of compounds that bind to an allosteric site on K-Ras.
64. • Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, Hu L, Sugimoto T, Ijiri Y, Takeda A et al.: In silico discovery of smallmolecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A 2013, 110:8182-8187. Describes the discovery of compounds by virtual screening and struc-ture- based design that bind to Ras and exhibit antiproliferative activity toward Ras-dependent cancer cells.
65. •• Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens PI et al.: Small molecule inhibition of the KRAS-PDEd interaction impairs oncogenic KRAS signalling. Nature 2013, 497:638-642. The discovery and first demonstration that small molecule chemical probes for PDEd suppress oncogenic KRAS signalling opening up new avenues of attack for the hitherto undruggable KRAS oncogene.
66. Molzan M, Kasper S, Röglin L, Skwarczynska M, Sassa T, Inoue T, Breitenbuecher F, Ohkanda J, Kato N, Schuler M et al.: Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers. ACS Chem Biol 2013, 8:1869-1875.
67. •• Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, Hsieh JT, Ahn JM, Raj GV: Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun 2013, 4:1923. The discovery of the first potent and selective peptidomimetic inhibitor of the PELP1-androgen receptor interaction and a corresponding inactive control compound. Cell-based and in vivo activity is demonstrated in models of androgen-dependent prostate cancer.
68. Bonnal S, Vigevani L, Valcárcel J: The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012, 11:847-859.
69. Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, Baselga J et al.: Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res 2013, 19 :6296-6304.
70. Nguyen GH, Dexheimer TS, Rosenthal AS, Chu WK, Singh DK, Mosedale G, Bachrati CZ, Schultz L, Sakurai M, Savitsky P et al.: A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem Biol 2013, 20:55-62.
71. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ: Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999, 286:971-974.
72. Watts CA, Richards FM, Bender A, Bond PJ, Korb O, Kern O, Riddick M, Owen P, Myers RM, Raff J et al.: Design, synthesis and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes. Chem Biol 2013, 20:1399-1410.
73. Wu J, Mikule K, Wang W, Su N, Petteruti P, Gharahdaghi F, Code E, Zhu X, Jacques K, Lai Z et al.: Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1. ACS Chem Biol 2013, 8:2201-2208.
74. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ et al.: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435 :677-681.
75. • Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia- Barrantes PM, Camper D, Chauder BA, Lee T, Olejniczak ET, Fesik SW: Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structurebased design. J Med Chem 2013, 56:15-30. Structure-based discovery of specific inhibitors of the pro-survival Bcl-2 family member Mcl-1 with selectivity over Bcl-xL and Bcl-2.
76. Eggert US: The why and how of phenotypic small-molecule screens. Nat Chem Biol 2013, 9:206-209.
77. Swinney DC, Anthony J: How were new medicines discovered? Nat Rev Drug Discov 2011, 10:507-519.
78. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S et al.: Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
79. Lehtiö L, Chi NW, Krauss S: Tankyrases as drug targets. FEBS J 2013, 280:3576-3593.
80. Shultz MD, Cheung AK, Kirby CA, Firestone B, Fan J, Chen CH, Chen Z, Chin DN, Dipietro L, Fazal A et al.: Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J Med Chem 2013, 56:6495-6511.
81. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D et al.: Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A 2013, 110:20224-20229.
82. •• Bassilana F, Carlson A, DaSilva JA, Grosshans B, Vidal S, Beck V, Wilmeringwetter B, Llamas LA, Showalter TB, Rigollier P et al.: Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39. Nat Chem Biol 2014, 10:343-349. Details the surprising discovery of an orphan GPCR implicated in hedge-hog pathway signalling. An impressive account of research to identify the biochemical target of a chemical tool discovered using a cell-based phenotypic screen.
83. •• Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M et al.: A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013, 3:1364-1377. Illustrates the power and utility of in silico bioinformatics-based approaches to highlight opportunities for the use of existing drugs in new clinical indications.
84. Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Jära˚s M, Puram R et al.: Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol 2013, 9:840-848.
85. Popovici-Muller J, Saunders JO, Salituro FG, Travins JM, Yan S, Zhao F, Gross S, Dang L, Yen KE, Yang H et al.: Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett 2012, 3:850-855.
86. Ward RA, Brassington C, Breeze AL, Caputo A, Critchlow S, Davies G, Goodwin L, Hassall G, Greenwood R, Holdgate GA et al.: Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. J Med Chem 2012, 55:3285-3306.
87. Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, Chesler L, Raynaud FI, Eccles SA, Collins I, Garrett MD: CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res 2012, 18:5650-5661.
88. Zhang Z, Chu XJ, Liu JJ, Ding Q, Zhang J, Bartkovitz D, Jiang N, Karnachi P, So SS, Tovar C et al.: Discovery of potent and orally active p53-MDM2 inhibitors RO5353 and RO2468 for potential clinical development. ACS Med Chem Lett 2013, 5:124-127.
89. • Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014, 370:997-1000. One of two papers describing favourable clinical outcomes and safety profile with an inhibitor of the delta isoform of PI3 kinase, idelalisib.
90. • Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A et al.: PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014, 370:1008-1018. One of two papers describing favourable clinical outcomes and safety profile with an inhibitor of the delta isoform of PI3 kinase, idelalisib.
91. •• Ali K, Soond DR, Piñeiro R, Hagemann T, Pearce W, Lim EL5, Bouabe H, Scudamore CL, Hancox T, Maecker H, Friedman L, Turner M5, Okkenhaug K, Vanhaesebroeck B: Inactivation of PI(3)K p110d breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014, 509 :407-411. An important paper showing that inhibition of the p110 delta isoform of PI3 kinase activates CD8+ cytotoxic T cells and induces tumour regression, broadening the scope of such inhibitors to solid cancers.
92. Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J, Dudley D et al.: Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem 2013, 56:4597-4610.
93. Neckers L, Workman P: Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012, 18:64-76.
94. Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, Que NS, Taldone T, Finotti P, Stephani RA et al.: Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol 2013, 9:677-684.
95. Schlecht R1, Scholz SR, Dahmen H, Wegener A, Sirrenberg C, Musil D, Bomke J, Eggenweiler HM, Mayer MP, Bukau B: Functional analysis of Hsp70 inhibitors. PLOS ONE 2013, 8:e78443.
96. Samant RS, Clarke PA, Workman P: E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells. Proc Natl Acad Sci U S A 2014, 18:6834-6839.
97. Polier S, Samant RS, Clarke PA, Workman P, Prodromou C, Pearl LH: ATP-competitive inhibitors block protein kinase recruitment to the HSP90-CDC37 system. Nat Chem Biol 2013, 5:307-312.
98. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S: ESR1 ligandbinding domain mutations in hormone-resistant breast cancer. Nat Genet 2013, 12:1439-1445.
99. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana- Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013, 12:1446-1451.
100. •• Krönke J, Udeshi ND, Narla A, Grauman PGN, Hurst GN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL: Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014, 343. Alongside ref [101], discovery by chemical proteomics that the thalidomide class of drugs exert their antitumour effects by activating the CRBN-CUL4 E3 ubiquitin ligase complex to degrade the IKZ transcription factors.
101. •• Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr: The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014, 343:305-309. In addition to ref [101], discovery by genetic screening that the thalidomide class of drugs exert their antitumour effects by activating the CRBN-CUL4 E3 ubiquitin ligase complex to degrade the IKZ transcription factors.
102. •• Fischer ES, Böhm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, Nagel J, Serluca F, Acker V, Lingaraju GM et al.: Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014 http://dx.doi.org/10.1038/nature13527. Powerful structure-function studies reveal how lenalidomide and related drugs bind to the CRBN complex and block the recruitment of endogenous substrates such as MEIS2 to the complex while promoting recruitment and degradation of neo-substrates such as the IKZ transcription factors - a fascinating drug-induced substrate switch mechanism that leads to anti-myeloma activity.
103. • Dahl G, Akerud T: Pharmacokinetics and the drug-target residence time concept. Drug Discov Today 2013, 18:697-707. Insightful perspective on the implications of slow offset kinetics in the context of pharmacokinetic profile.
104. Singh J, Petter RC, Baillie TA, Whitty A: The resurgence of covalent drugs. Nat Rev Drug Discov 2011, 10:307-317.
105. DeVore NM, Scott EE: Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 2012, 482 :116-119.
106. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M et al.: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
107. •• Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG et al.: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42. Describes favourable clinical outcomes and safety profile with ibrutinib in CLL including a significantly extended pharmacodynamic duration of action compared with pharmacokinetic exposure, consistent with irreversible target engagement.
108. •• Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551. Describes the elegant discovery of compounds which selectively bind to the cysteine of oncogenic G12C mutant K-Ras and reveals a new opportunity for targeting K-Ras with small molecule covalent inhibitors.
109. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy free. Nat Rev Cancer 2012, 12:252-264.
110. Vanneman M, Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment free. Nat Rev Cancer 2012:237-251.
111. Krummel MF, Allison JP: Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Immunol 2011, 7:3459-3465.